{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:31:05Z","timestamp":1792978265784,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Algerian National Research Program FNRSDT"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12253-017-0242-2","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T14:46:08Z","timestamp":1494081968000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients"],"prefix":"10.1007","volume":"24","author":[{"given":"Hadjer","family":"Gaceb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7338-1252","authenticated-orcid":false,"given":"Farid","family":"Cherbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabah","family":"Bakour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhalim","family":"Ould-Rouis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassen","family":"Mahfouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,6]]},"reference":[{"key":"242_CR1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008 GLOBOCAN. Int J Cancer 127:2893\u20132917","journal-title":"Int J Cancer"},{"key":"242_CR2","unstructured":"GLOBOCAN: Breast cancer incidence and mortality worldwide (2012) International agency for research on cancer; 2012. http:\/\/globocan.iarc.fr\/old\/FactSheets\/cancers\/breast-new.asp . Accessed 21 March 2016"},{"key":"242_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molonc.2010.04.006","volume":"4","author":"F Podo","year":"2010","unstructured":"Podo F, Buydens LMC, Degani H et al (2010) Triple_negative breast cancer: present challenges and new perspectives. Mol Oncol 4:209\u2013229","journal-title":"Mol Oncol"},{"key":"242_CR4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrclinonc.2010.154","volume":"7","author":"L Carey","year":"2010","unstructured":"Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7:683\u2013692","journal-title":"Nat Rev Clin Oncol"},{"key":"242_CR5","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI et al (2007) Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u20134434","journal-title":"Clin Cancer Res"},{"key":"242_CR6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492\u20132502","journal-title":"JAMA"},{"key":"242_CR7","first-page":"1721","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer. Registry 109:1721\u20131728","journal-title":"Registry"},{"key":"242_CR8","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2008.19.6873","volume":"27","author":"D Huo","year":"2009","unstructured":"Huo D, Ikpatt F, Khramtsov A et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple negative breast cancer. J Clin Oncol 27:4515\u20134521","journal-title":"J Clin Oncol"},{"key":"242_CR9","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1002\/cncr.25276","volume":"116","author":"A Stark","year":"2010","unstructured":"Stark A, Kleer CG, Martin I et al (2010) African ancestry and higher prevalence of triple negative breast cancer: findings from an international study. Cancer 116:4926\u20134932","journal-title":"Cancer"},{"key":"242_CR10","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/cncr.25862","volume":"117","author":"KC Amirikia","year":"2011","unstructured":"Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 117:2747\u20132753","journal-title":"Cancer"},{"key":"242_CR11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000341541","volume":"83","author":"M Ly","year":"2012","unstructured":"Ly M, Antoine M, Demb\u00e9l\u00e9 AK et al (2012) High incidence of triple-negative tumors in sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257\u2013263","journal-title":"Oncology"},{"key":"242_CR12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2407-11-292","volume":"11","author":"Y Su","year":"2011","unstructured":"Su Y, Zheng Y, Zheng W et al (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population- based cohort study. BMC Cancer 11:292","journal-title":"BMC Cancer"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-014-2882-1","volume":"144","author":"MP Banegas","year":"2014","unstructured":"Banegas MP, Tao L, Altekruse S et al (2014) Heterogeneity of breast cancer sub-types and survival among Hispanic women with invasive breast cancer in California. Breast Cancer Res Treat 144:625\u2013634","journal-title":"Breast Cancer Res Treat"},{"key":"242_CR14","first-page":"337","volume":"4","author":"M Singh","year":"2014","unstructured":"Singh M, Ding Y, Zhang LY et al (2014) Distinct breast cancer subtypes in women with early- onset disease across races. Am J Cancer Res 4:337\u2013352","journal-title":"Am J Cancer Res"},{"key":"242_CR15","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1111\/ajco.12034","volume":"10","author":"A Fourati","year":"2014","unstructured":"Fourati A, Boussen H, El May MV et al (2014) Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol 10:e69\u2013e74","journal-title":"Asia Pac J Clin Oncol"},{"key":"242_CR16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2009.12.002","volume":"36","author":"A Bosch","year":"2010","unstructured":"Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36:206\u2013205","journal-title":"Cancer Treat Rev"},{"key":"242_CR17","doi-asserted-by":"publisher","unstructured":"Wong ESY, Shekar S, Chan CHT et al Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population. PLoS ONE 7:e0134408. doi: 10.1371\/journal.pone.0134408","DOI":"10.1371\/journal.pone.0134408"},{"key":"242_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00432-010-0957-x","volume":"137","author":"TC De Ruitjter","year":"2011","unstructured":"De Ruitjter TC, Veeck J, Hoon JPJ, Van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137:183\u2013192","journal-title":"J Cancer Res Clin Oncol"},{"key":"242_CR19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/bjc.2012.31","volume":"106","author":"L Robertson","year":"2012","unstructured":"Robertson L, Hanson H, Seal S et al (2012) BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 106:1234\u20131238","journal-title":"Br J Cancer"},{"key":"242_CR20","first-page":"2025","volume":"7","author":"KN Stevens","year":"2012","unstructured":"Stevens KN, Vachon CM, Couch FJ (2012) Genetic susceptibility to triple-negative breast cancer. Cancer Res 7:2025\u20132030","journal-title":"Cancer Res"},{"key":"242_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047993","volume":"7","author":"F Pern","year":"2012","unstructured":"Pern F, Bogdanova N, Sch\u00fcrmann LM et al (2012) Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital based series of German patients with triple-negative breast cancer. PLoS One 7:e47993. doi: 10.1371\/journal.pone.0047993","journal-title":"PLoS One"},{"key":"242_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly (ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123\u2013134","journal-title":"N Engl J Med"},{"key":"242_CR23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235\u2013244","journal-title":"Lancet"},{"key":"242_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BD-130348","volume":"34","author":"F Cherbal","year":"2013","unstructured":"Cherbal F, Bakour R, Adane S, Boualga K (2013) BRCA1 and BRCA2 germline mutation spectrum in hereditary breast\/ovarian cancer families from Maghrebian countries. Breast Dis 34:1\u20138","journal-title":"Breast Dis"},{"key":"242_CR25","first-page":"131","volume-title":"Classification of malignant tumors","author":"LH Sobin","year":"2002","unstructured":"Sobin LH, Wittekind CH (2002) Breast tumors. In: Sobin LH, Wittekinds CH (eds) Classification of malignant tumors, 6th edn. Wiley-Liss, Geneva, pp 131\u2013142","edition":"6th"},{"key":"242_CR26","doi-asserted-by":"crossref","first-page":"285e6","DOI":"10.1016\/j.breast.2015.01.014","volume":"24","author":"I Pennacchia","year":"2015","unstructured":"Pennacchia I, Carbone A, Di Cerbo A, Vecchio FM, Arena V (2015) 2013 ASCO\/CAP updated guidelines for human epidermal growth factor receptor 2 testing: impact on routine practice. Breast 24:285e6","journal-title":"Breast"},{"key":"242_CR27","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ, Panel members (2011) Strategies for sub- types \u2013 dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736\u20131747. doi: 10.1093\/annonc\/mdr304","journal-title":"Ann Oncol"},{"key":"242_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ, Panel Members (2015) Tailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533\u20131546. doi: 10.1093\/annonc\/mdv221","journal-title":"Ann Oncol"},{"key":"242_CR29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1155\/2010\/585278","volume":"28","author":"F Cherbal","year":"2010","unstructured":"Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P (2010) BRCA1 and BRCA2 germline mutations screening in Algerian breast\/ovarian cancer families. Dis Markers 28:377\u2013384","journal-title":"Dis Markers"},{"key":"242_CR30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1472-6874-12-35","volume":"12","author":"G Rais","year":"2012","unstructured":"Rais G, Raissouni S, Aitelhaj M et al (2012) Triple-negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of oncology. BMC Womens Health 12:35","journal-title":"BMC Womens Health"},{"key":"242_CR31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00432-013-1478-1","volume":"139","author":"P Minicozzi","year":"2013","unstructured":"Minicozzi P, Bella F, Toss A et al (2013) Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. J Cancer Res Clin Oncol 139:1569\u20131577","journal-title":"J Cancer Res Clin Oncol"},{"key":"242_CR32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/jnci\/djs264","volume":"104","author":"CA Clarke","year":"2012","unstructured":"Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104:1094\u20131101","journal-title":"J Natl Cancer Inst"},{"key":"242_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","volume":"109","author":"EA Rakha","year":"2007","unstructured":"Rakha EA, El-Sayed ME, Green AR (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25\u201332","journal-title":"Cancer"},{"key":"242_CR34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1359-6349(08)70763-8","volume":"6","author":"J Ann","year":"2008","unstructured":"Ann J, Kang S, Kwun K (2008) Clinicopathologic characteristics of triple negative breast cancer in early stages. Eur J Cancer Supp 6:183","journal-title":"Eur J Cancer Supp"},{"key":"242_CR35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7150\/jca.10944","volume":"7","author":"J Qiu","year":"2016","unstructured":"Qiu J, Xue X, Hu C et al (2016) Comparison of Clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 7:167\u2013173","journal-title":"J Cancer"},{"key":"242_CR36","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.7314\/APJCP.2013.14.6.3779","volume":"14","author":"CY Li","year":"2013","unstructured":"Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J (2013) Clinicopathological and prognostic characteristics of triple-negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev 14:3779\u20133784","journal-title":"Asian Pac J Cancer Prev"},{"key":"242_CR37","first-page":"187","volume":"360","author":"Collaborative group on Hormonal factors in Breast Cancer","year":"2012","unstructured":"Collaborative group on Hormonal factors in Breast Cancer (2012) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360:187\u2013195","journal-title":"Lancet"},{"key":"242_CR38","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1010539513488795","volume":"25","author":"T Anothaisintawee","year":"2013","unstructured":"Anothaisintawee T, Wiratkapun C, Lerdsitthichai P et al (2013) Risk factors of breast cancer: a systematic revew and meta-analysis. Asia Pac J Public Health 25:368\u20134943","journal-title":"Asia Pac J Public Health"},{"key":"242_CR39","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/annonc\/mdv379","volume":"26","author":"F Islami","year":"2015","unstructured":"Islami F, Liu Y, Jemal A et al (2015) Breastfeeding and breast cancer risk by receptor status- a systematic review and meta-analysis. Ann Oncol 26:2398\u20132407","journal-title":"Ann Oncol"},{"key":"242_CR40","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1002\/cncr.25443","volume":"116","author":"SS Shinde","year":"2010","unstructured":"Shinde SS, Forman MR, Kuerer HM et al (2010) Higher parity and shorter breast feeding duration: association with triple-negative phenotype of breast cancer. Cancer 116:4933\u20134943","journal-title":"Cancer"},{"key":"242_CR41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/1471-2407-10-664","volume":"10","author":"SY Jung","year":"2010","unstructured":"Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal a breast cancer: a retrospective cohort study. BMC Cancer 10:664","journal-title":"BMC Cancer"},{"issue":"1","key":"242_CR42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3349\/ymj.2011.52.1.89","volume":"52","author":"JS Koo","year":"2011","unstructured":"Koo JS, Jung WH (2011) Clinicopathlogic and Immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 52(1):89\u201397","journal-title":"Yonsei Med J"},{"key":"242_CR43","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1200\/JCO.2010.33.6446","volume":"29","author":"E Lee","year":"2011","unstructured":"Lee E, McKean-Cowdin R, Ma H et al (2011) Characteristics of triple negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29:4373\u20134380","journal-title":"J Clin Oncol"},{"key":"242_CR44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-015-3293-7","volume":"50","author":"MW Wong-Brown","year":"2015","unstructured":"Wong-Brown MW, Meldrum CJ, Carpenter JE et al (2015) Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 50:71\u201380","journal-title":"Breast Cancer Res Treat"},{"key":"242_CR45","doi-asserted-by":"crossref","unstructured":"Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1-BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029\u20132034","DOI":"10.1158\/1078-0432.CCR-03-1061"},{"key":"242_CR46","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082\u20131089","journal-title":"Clin Cancer Res"},{"key":"242_CR47","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM et al (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118:2787\u20132795","journal-title":"Cancer"},{"key":"242_CR48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-012-2348-2","volume":"137","author":"S Rummel","year":"2013","unstructured":"Rummel S, Varner E, Shriver CD, Ellsworth RE (2013) Evaluation of BRCA1 mutations in an unselected patient population with triple- negative breast cancer. Breast Cancer Res Treat 137:119\u2013125","journal-title":"Breast Cancer Res Treat"},{"key":"242_CR49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1414","author":"FJ Couch","year":"2014","unstructured":"Couch FJ, Hart SN, Sharma P et al (2014) Inherited mutations in 17 breast cancer susceptibility genes among a large triple negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. doi: 10.1200\/JCO.2014.57.1414","journal-title":"J Clin Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-017-0242-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0242-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0242-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T02:24:54Z","timestamp":1602037494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-017-0242-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s12253-017-0242-2","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,6]]}}}